Global Adenomyosis Treatment Market, By Type (Focal, Adenomyoma, Diffuse, Others), Diagnosis (Endometrial Biopsy, Ultrasound, Magnetic Resonance Imaging (MRI), Others), Treatment (Anti-Inflammatory Drugs, Hormone Medications, Hysterectomy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
The adenomyosis treatment market is forecasted to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a robust CAGR of 5.10% in the above-mentioned research forecast period. Increased funds from research and development, rise in occurrence of adenomyosis, awareness and knowledge about the disease advent of new drugs, medical technology and therapies are the factors responsible for the growth of the adenomyosis treatment market.
The adenomyosis is the existence of ectopic endometrial glands and stroma which is surrounded by hyperplastic smooth muscle in the myometrium. It is a uterine disorder associated with pelvic pain, abnormal uterine bleeding (AUB) and infertility. The two different pathological forms are diffused and local. Adenomyosis treatment depends on how close the patient is to the stage of adenomyosis. Adenomyosis usually ceases after menopause. The treatment options are the anti-inflammatory drugs such as ibuprofen, hormonal medications such as hormone containing patches which reduce the excess bleeding and pain linked with adenomyosis. Hysterectomy is applied when the pain is serious and the gynaecologist may suggest removing the uterus.
The latest technological advancement for treatment of adenomyosis is the levonorgestrel-releasing intrauterine system (LNG-IUS). It’s an effective, reversible and long-term potential treatment used successfully to treat adenomyosis. The treatment curbs menstrual bleeding, pain and uterine volume and has an overall satisfaction of 72%. New drugs such as selective progesterone receptor modulators, aromatase inhibitors, valproic acid and anti-platelet therapy are under development for the treatment of adenomyosis. The rise in prevalence of adenomyosis is the major factor driving the adenomyosis treatment market growth. A prevalence of 20% to 35% of women who suffered adenomyosis has been reported. Rise in funds from research and development (R&D) and government, rise in occurrence of adenomyosis, awareness and knowledge about the disease advent of new drugs, medical technology and therapies are the factors responsible for the growth of the adenomyosis treatment market. However, certain challenges faced are increased cost, lack of certain medical infrastructure and treatment to cure adenomyosis will tamper the adenomyosis treatment market growth.
This adenomyosis treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the adenomyosis treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Adenomyosis Treatment Market Scope and Market Size
The adenomyosis treatment market is segmented on the basis of type, diagnosis and treatment. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the adenomyosis treatment market is segmented into focal, adenomyoma, diffuse and others.
- On the basis of diagnosis, the adenomyosis treatment market is bifurcated into endometrial biopsy, ultrasound, magnetic resonance imaging (MRI) and others. Ultrasound is sub-segmented into transabdominal and transvaginal/endovaginal.
- On the basis of treatment, the adenomyosis treatment market has also been segmented into anti-inflammatory drugs, hormone medications, hysterectomy and others. Anti-inflammatory drugs are sub-segmented into ibuprofen, motrin IB, advil and others. Hormone medications are sub-segmented into gonadotropin-releasing hormone (GnRH) agonists, aromatase inhibitors and others. Hysterectomy is sub-segmented into supracervial or subtotal hysterectomy, total hysterectomy and radical hysterectomy.
Global Adenomyosis Treatment Market Country Level Analysis
Global adenomyosis treatment market is analysed and market size information is provided by country, type, diagnosis and treatment as referenced above.
The countries covered in the global adenomyosis treatment market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, the U.S. in North America is expected to hold the largest market share followed by Europe. The growth frequency in Western European countries is higher. The Asia-Pacific is anticipated to become the fastest growing market in the estimate period due to the factors such as rise in knowledge about the disease and treatments, upcoming healthcare infrastructure and increased disbursement on healthcare. However, Middle East and Africa (MEA) are probably to have a less growth in market revenue due to minimum cognizance about the medical devices and treatment.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis : Global Adenomyosis Treatment Market
Global adenomyosis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to adenomyosis treatment market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the adenomyosis treatment market in the growth period.
Competitive Landscape and Global Adenomyosis Treatment Market Share Analysis
Global adenomyosis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global adenomyosis treatment market.
The major players covered in the global adenomyosis treatment market are Bayer AG, Ferring B.V., Johnson & Johnson Services, Inc., Novartis AG, Merck KGaA, Pfizer Inc., Speciality European Pharma among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The major players have sponsored for the clinical trials of certain drugs for treatment of adenomyosis. The dienogest (visanne) by Bayer AG is in Phase III clinical trial.